Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Supercritical CO2-Processed Micronized Acellular Dermal Matrix Enhances Soft-Tissue Regeneration: A Preclinical and Clinical Study.

Created on 16 Nov 2026

Authors

Heewoong Yang, Eun Hee Ha, Sehoon Yoon, Haejin Lew, Ying Zhu, Duri Lee, Jin Woo Bae, Yongwoo Shin, Hak Chang, Ki Yong Hong

Published in

Plastic and reconstructive surgery. Nov 16, 2026. Epub Nov 16, 2026.

Abstract

Micronized acellular dermal matrix (mADM) derived from decellularized human dermis is used in breast reconstruction to address soft-tissue deficiencies and peri-implant deformities. Although mADM processed using supercritical carbon dioxide (SC-mADM) has previously been evaluated with respect to its fabrication and biocompatibility, its clinical application has not yet been investigated. Therefore, we aimed to evaluate the biological responses to SC-mADM and its preliminary clinical applicability as an injectable scaffold.
In a rabbit model, 3 mL of either low-concentration (7.5%) or high-concentration (25%) SC-mADM was injected and assessed at 3 and 6 months. Volume retention was quantified using micro-computed tomography. Histologic analyses and quantitative reverse transcription polymerase chain reaction analyses of genes associated with angiogenesis and tissue remodeling were performed. Based on these findings, a prospective clinical study involving four patients and five breasts was conducted to assess the correction of post-reconstruction rippling.
High-concentration SC-mADM demonstrated greater volume retention than low-concentration SC-mADM at both 3 and 6 months. At 6 months, CD31-positive vascular density was higher in the high-concentration group, accompanied by increased expression of angiogenesis- and remodeling-related genes. Clinically, injections of high-concentration mADM resulted in improvement in rippling and peri-implant depressions. Magnetic resonance imaging at 4 months demonstrated an early mean region-level volume retention rate of 57.6%.
Injected mADM exhibited concentration-dependent tissue integration. These preliminary findings suggest that SC-mADM may serve as a biologically active injectable scaffold for minimally invasive contour correction in breast reconstruction. Further validation in larger studies with longer follow-up periods is warranted.Clinical Relevance Statement: mADM is a promising advanced soft-tissue filler that supports volume retention and host-tissue integration. The biological responses observed in the rabbit model provide preclinical evidence supporting its potential use in soft-tissue augmentation and repair.

PMID:
43037578
Bibliographic data and abstract were imported from PubMed on 16 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 76
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement